LifeMD, Inc. (NASDAQ:LFMD) Short Interest Update

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) saw a significant decline in short interest in the month of May. As of May 15th, there was short interest totalling 3,860,000 shares, a decline of 27.7% from the April 30th total of 5,340,000 shares. Currently, 10.7% of the shares of the company are short sold. Based on an average trading volume of 1,770,000 shares, the short-interest ratio is currently 2.2 days.

Insider Transactions at LifeMD

In other LifeMD news, CMO Jessica Friedeman sold 30,000 shares of the business's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $5.66, for a total transaction of $169,800.00. Following the completion of the transaction, the chief marketing officer now directly owns 170,000 shares in the company, valued at $962,200. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Justin Schreiber sold 21,995 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $7.53, for a total transaction of $165,622.35. Following the transaction, the chief executive officer now owns 2,553,726 shares of the company's stock, valued at approximately $19,229,556.78. This represents a 0.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 126,995 shares of company stock worth $1,036,172 over the last quarter. Company insiders own 18.40% of the company's stock.

Hedge Funds Weigh In On LifeMD

Several institutional investors have recently made changes to their positions in LFMD. Marshall Wace LLP raised its holdings in shares of LifeMD by 522.9% in the 4th quarter. Marshall Wace LLP now owns 371,473 shares of the company's stock worth $1,839,000 after acquiring an additional 311,841 shares during the last quarter. Nuveen LLC purchased a new stake in shares of LifeMD during the 1st quarter worth approximately $1,545,000. Royce & Associates LP increased its stake in shares of LifeMD by 23.9% during the 4th quarter. Royce & Associates LP now owns 1,115,991 shares of the company's stock worth $5,524,000 after purchasing an additional 214,950 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of LifeMD by 21.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,294 shares of the company's stock worth $4,610,000 after purchasing an additional 165,378 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in LifeMD by 45.2% in the 4th quarter. Renaissance Technologies LLC now owns 510,000 shares of the company's stock worth $2,524,000 after buying an additional 158,796 shares during the period. Institutional investors and hedge funds own 35.52% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have commented on LFMD. HC Wainwright restated a "buy" rating and set a $14.00 price objective on shares of LifeMD in a research report on Wednesday, April 30th. B. Riley upgraded shares of LifeMD to a "strong-buy" rating in a research report on Tuesday, March 11th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $15.00 price objective on shares of LifeMD in a research report on Tuesday, March 11th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $11.00.

LifeMD Price Performance

Shares of LifeMD stock traded down $0.21 during trading on Thursday, hitting $12.08. The company's stock had a trading volume of 1,920,976 shares, compared to its average volume of 1,003,357. LifeMD has a 52 week low of $3.99 and a 52 week high of $13.25. The stock has a market cap of $549.01 million, a price-to-earnings ratio of -18.88 and a beta of 2.42. The stock has a 50-day moving average price of $7.83 and a two-hundred day moving average price of $6.41.

LifeMD (NASDAQ:LFMD - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.05. The company had revenue of $65.70 million for the quarter, compared to analyst estimates of $62.47 million. On average, equities analysts predict that LifeMD will post -0.56 EPS for the current fiscal year.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.